How vaccine maker Dynavax tested itself and found a corporate cure
The company brought in $900 million selling its immune-stimulating adjuvant to others seeking Covid vaccines. Now it's turning that cash into a pipeline of potential vaccines against shingles, plague and more.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Covid Vaccine | Health Management | Pharmaceuticals | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines